Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial
Beatrice Seddon,Sandra J. Strauss,Jeremy Whelan,Michael F. Leahy,Penella J. Woll,Fiona Cowie,Christian Rothermundt,Zoe Wood,Charlotte Benson,Nasim Ali,Maria Marples,Gareth J. Veal,David Jamieson,Katja Küver,Roberto Tirabosco,Sharon Forsyth,Stephen Nash,Hakim-Moulay Dehbi,Sandy Beare +18 more
TLDR
This study compared gemcitabine and docetaxel versus doxorubicin as first-line treatment for advanced or metastatic soft-tissue sarcoma and found that the proportion of patients alive and progression free at 24 weeks in the intention-to-treat population did not differ.Abstract:
Summary Background For many years, first-line treatment for locally advanced or metastatic soft-tissue sarcoma has been doxorubicin. This study compared gemcitabine and docetaxel versus doxorubicin as first-line treatment for advanced or metastatic soft-tissue sarcoma. Methods The GeDDiS trial was a randomised controlled phase 3 trial done in 24 UK hospitals and one Swiss Group for Clinical Cancer Research (SAKK) hospital. Eligible patients had histologically confirmed locally advanced or metastatic soft-tissue sarcoma of Trojani grade 2 or 3, disease progression before enrolment, and no previous chemotherapy for sarcoma or previous doxorubicin for any cancer. Patients were randomly assigned 1:1 to receive six cycles of intravenous doxorubicin 75 mg/m 2 on day 1 every 3 weeks, or intravenous gemcitabine 675 mg/m 2 on days 1 and 8 and intravenous docetaxel 75 mg/m 2 on day 8 every 3 weeks. Treatment was assigned using a minimisation algorithm incorporating a random element. Randomisation was stratified by age (≤18 years vs >18 years) and histological subtype. The primary endpoint was the proportion of patients alive and progression free at 24 weeks in the intention-to-treat population. Adherence to treatment and toxicity were analysed in the safety population, consisting of all patients who received at least one dose of their randomised treatment. The trial was registered with the European Clinical Trials (EudraCT) database (no 2009–014907–29) and with the International Standard Randomised Controlled Trial registry (ISRCTN07742377), and is now closed to patient entry. Findings Between Dec 3, 2010, and Jan 20, 2014, 257 patients were enrolled and randomly assigned to the two treatment groups (129 to doxorubicin and 128 to gemcitabine and docetaxel). Median follow-up was 22 months (IQR 15·7–29·3). The proportion of patients alive and progression free at 24 weeks did not differ between those who received doxorubicin versus those who received gemcitabine and docetaxel (46·3% [95% CI 37·5–54·6] vs 46·4% [37·5–54·8]); median progression-free survival (23·3 weeks [95% CI 19·6–30·4] vs 23·7 weeks [18·1–20·0]; hazard ratio [HR] for progression-free survival 1·28, 95% CI 0·99–1·65, p=0·06). The most common grade 3 and 4 adverse events were neutropenia (32 [25%] of 128 patients who received doxorubicin and 25 [20%] of 126 patients who received gemcitabine and docetaxel), febrile neutropenia (26 [20%] and 15 [12%]), fatigue (eight [6%] and 17 [14%]), oral mucositis (18 [14%] and two [2%]), and pain (ten [8%] and 13 [10%]). The three most common serious adverse events, representing 111 (39%) of all 285 serious adverse events recorded, were febrile neutropenia (27 [17%] of 155 serious adverse events in patients who received doxorubicin and 15 [12%] of 130 serious adverse events in patients who received gemcitabine and docetaxel, fever (18 [12%] and 19 [15%]), and neutropenia (22 [14%] and ten [8%]). 154 (60%) of 257 patients died in the intention-to-treat population: 74 (57%) of 129 patients in the doxorubicin group and 80 (63%) of 128 in the gemcitabine and docetaxel group. No deaths were related to the treatment, but two deaths were due to a combination of disease progression and treatment. Interpretation Doxorubicin should remain the standard first-line treatment for most patients with advanced soft-tissue sarcoma. These results provide evidence for clinicians to consider with their patients when selecting first-line treatment for locally advanced or metastatic soft-tissue sarcoma. Funding Cancer Research UK, Sarcoma UK, and Clinical Trial Unit Kantonsspital St Gallen.read more
Citations
More filters
Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study
Martee L. Hensley,A. Miller,David M. O'Malley,Robert S. Mannel,Kian Behbakht,Jamie N. Bakkum-Gamez,Helen Michael +6 more
TL;DR: In this paper, the authors used a double-blind, placebo-controlled trial to determine whether the addition of bevacizumab to gemcitabine-docetaxel increases progression-free survival (PFS) in uLMS.
Journal ArticleDOI
Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Lorenzo D'Ambrosio,Nathan Touati,Jean-Yves Blay,Giovanni Grignani,Ronan Flippot,Anna M. Czarnecka,Anna M. Czarnecka,Sophie Piperno-Neumann,Javier Martin-Broto,Roberta Sanfilippo,Daniela Katz,Florence Duffaud,Bruno Vincenzi,Dan Stark,Filomena Mazzeo,Armin Tuchscherer,Christine Chevreau,Jenny Sherriff,Anna Estival,Saskia Litière,Ward Sents,Isabelle Ray-Coquard,Francesco Tolomeo,Axel Le Cesne,Piotr Rutkowski,Piotr Rutkowski,Silvia Stacchiotti,Bernd Kasper,Hans Gelderblom,Alessandro Gronchi +29 more
TL;DR: This study retrospectively evaluated doxorubicin plus dacarbazine, dox orubic in plus ifosfamide, and doxorbicin alone as first‐line treatments for advanced/metastatic leiomyosarcoma treated at European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC‐STBSG) sites.
Journal ArticleDOI
First-Line Therapy for Metastatic Soft Tissue Sarcoma.
Megan Meyer,Mahesh Seetharam +1 more
TL;DR: The data of the currently approved therapies in metastatic soft tissue sarcoma, with the principal focus on first-line therapies is summarized, and the recent encouraging data with PDGFR-targeted antibody with doxorubicin are reviewed.
Journal ArticleDOI
TP53 in bone and soft tissue sarcomas.
TL;DR: Nine bone and soft tissue sarcomas for which TP53 plays a crucial tumor suppressive role are outlined and new targeting strategies for TP53 have been discovered: restoration of wild-type p53 activity through inhibition of TP53 negative regulators, reactivation of the wtp53 activity from mutp53, and targeting of vulnerabilities in cells with TP53 deletions or mutations.
Journal ArticleDOI
Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma: A Phase 1/2 Nonrandomized Clinical Trial.
Seth M. Pollack,Seth M. Pollack,Mary W. Redman,Mary W. Redman,Kelsey Baker,Michael J. Wagner,Michael J. Wagner,Brett Schroeder,Brett Schroeder,Elizabeth T. Loggers,Elizabeth T. Loggers,Kathryn Trieselmann,Kathryn Trieselmann,Vanessa C. Copeland,Vanessa C. Copeland,Shihong Zhang,Graeme Black,Sabrina McDonnell,Sabrina McDonnell,Jeffrey Gregory,Jeffrey Gregory,Rylee Johnson,Rylee Johnson,Roxanne Moore,Roxanne Moore,Robin L. Jones,Lee D. Cranmer,Lee D. Cranmer +27 more
TL;DR: This nonrandomized clinical trial evaluates the use of doxorubicin and pembrolizumab in patients with metastatic/unresectable anthracycline-naive sarcoma.
References
More filters
Journal ArticleDOI
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
Elizabeth Eisenhauer,P. Therasse,Jan Bogaerts,Lawrence H. Schwartz,Daniel J. Sargent,Robert Ford,Janet Dancey,S. Arbuck,S. Gwyther,Margaret M. Mooney,Larry Rubinstein,Lalitha K. Shankar,Lori E. Dodd,Robert M. Kaplan,Denis Lacombe,Jaap Verweij +15 more
TL;DR: The revised RECIST includes a new imaging appendix with updated recommendations on the optimal anatomical assessment of lesions, and a section on detection of new lesions, including the interpretation of FDG-PET scan assessment is included.
Journal ArticleDOI
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†
Paolo G. Casali,N. Abecassis,Sebastian Bauer,R. Biagini,Stefan S. Bielack,Sylvie Bonvalot,Ioannis Boukovinas,Judith V.M.G. Bovée,Thomas Brodowicz,Javier Martin Broto,Angela Buonadonna,E. de Álava,A. P. Dei Tos,X.G. del Muro,Palma Dileo,Mikael Eriksson,Alexander Fedenko,Virginia Ferraresi,Andrea Ferrari,Silvia Ferrari,A.M. Frezza,Silvia Gasperoni,Hans Gelderblom,Thierry Gil,Giovanni Grignani,Alessandro Gronchi,Rick L. Haas,A. Hannu,B. Hassan,Peter Hohenberger,Rolf D. Issels,Heikki Joensuu,Robin L. Jones,Ian Judson,Paul C Jutte,Suzanne E. J. Kaal,Bernd Kasper,Katerina Kopeckova,D.A. Krakorova,A. Le Cesne,Iwona Lugowska,Ofer Merimsky,Michael Montemurro,Maria Abbondanza Pantaleo,R. Piana,Piero Picci,S. Piperno-Neumann,Antonio López Pousa,Peter Reichardt,M.H. Robinson,Piotr Rutkowski,Akmal Safwat,Patrick Schöffski,Stefan Sleijfer,Silvia Stacchiotti,K. Sundby Hall,M. Unk,F. van Coevorden,W.T.A. van der Graaf,Jeremy Whelan,Eva Wardelmann,Olga Zaikova,Jean-Yves Blay +62 more
Journal ArticleDOI
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
Ian Judson,Jaap Verweij,Hans Gelderblom,Jörg T. Hartmann,Jörg T. Hartmann,Patrick Schöffski,Jean-Yves Blay,J. Martijn Kerst,Josef Sufliarsky,Jeremy Whelan,Peter Hohenberger,Anders Krarup-Hansen,Thierry Alcindor,Thierry Alcindor,Sandrine Marreaud,Saskia Litière,Catherine Hermans,Cyril Fisher,Pancras C.W. Hogendoorn,A Paolo dei Tos,Winette T. A. van der Graaf +20 more
TL;DR: This phase 3 randomised controlled trial assessed whether dose intensification of doxorubicin with ifosfamide improves survival of patients with advanced soft-tissue sarcoma compared with doxorbicin alone.
Journal ArticleDOI
Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma: Results of a Phase II Trial
Martee L. Hensley,Robert G. Maki,Ennapadam Venkatraman,Gennifer Geller,Meghan Lovegren,Carol Aghajanian,Paul Sabbatini,William P. Tong,Richard Barakat,David R. Spriggs +9 more
TL;DR: Gemcitabine plus docetaxel is tolerable and highly active in treated and untreated patients with LMS, and Hematologic toxicity was common, but neutropenic fever and bleeding events were rare.
Journal ArticleDOI
Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas
Robert G. Maki,J. Kyle Wathen,Shreyaskumar Patel,Dennis A. Priebat,Scott H. Okuno,Brian L. Samuels,Michael P. Fanucchi,David C. Harmon,Scott M. Schuetze,Denise Reinke,Peter F. Thall,Robert S. Benjamin,Laurence H. Baker,Martee L. Hensley +13 more
TL;DR: Gem citabine as a single agent and the combination of gemcitabine and docetaxel have activity in patients with metastatic soft tissue sarcoma are found to have activity.
Related Papers (5)
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
Ian Judson,Jaap Verweij,Hans Gelderblom,Jörg T. Hartmann,Jörg T. Hartmann,Patrick Schöffski,Jean-Yves Blay,J. Martijn Kerst,Josef Sufliarsky,Jeremy Whelan,Peter Hohenberger,Anders Krarup-Hansen,Thierry Alcindor,Thierry Alcindor,Sandrine Marreaud,Saskia Litière,Catherine Hermans,Cyril Fisher,Pancras C.W. Hogendoorn,A Paolo dei Tos,Winette T. A. van der Graaf +20 more
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
Winette T. A. van der Graaf,Jean-Yves Blay,Sant P. Chawla,Dong Wan Kim,B. Bui-Nguyen,Paolo G. Casali,Patrick Schöffski,Massimo Aglietta,Arthur P. Staddon,Yasuo Beppu,Axel Le Cesne,Hans Gelderblom,Ian Judson,Nobuhito Araki,M. Ouali,Sandrine Marreaud,Rachel Hodge,Mohammed R. Dewji,Corneel Coens,George D. Demetri,Christopher D.M. Fletcher,Angelo Paolo Dei Tos,Peter Hohenberger +22 more
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
Patrick Schöffski,Sant P. Chawla,Robert G. Maki,Antoine Italiano,Hans Gelderblom,Edwin Choy,Giovanni Grignani,Veridiana Pires de Camargo,Sebastian Bauer,Sun Young Rha,Jean-Yves Blay,Peter Hohenberger,D. R. D'Adamo,Matthew Guo,Bartosz Chmielowski,Axel Le Cesne,George D. Demetri,Shreyaskumar Patel +17 more
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial
George D. Demetri,Margaret von Mehren,Robin L. Jones,Martee L. Hensley,Scott M. Schuetze,Arthur P. Staddon,Mohammed M. Milhem,Anthony D. Elias,Kristen N. Ganjoo,Hussein Tawbi,Brian A. Van Tine,Alexander I. Spira,Andrew Dean,Nushmia Z. Khokhar,Youn C. Park,Roland Elmar Knoblauch,Trilok V. Parekh,Robert G. Maki,Shreyaskumar Patel +18 more